What is Synthace?
Based in London, UK, and Boston, US, Synthace is at the forefront of computer-aided biology, developing innovative solutions to streamline biological discovery and optimization processes. Their proprietary cloud software platform, Antha, is designed to empower biologists by enabling them to program lab automation without requiring traditional coding expertise. The platform features a user-friendly graphical interface, developed with biologists in mind, which facilitates the automation of entire experimental workflows, from initial planning and execution to data collection and analysis. This approach significantly enhances research efficiency and accelerates the pace of scientific breakthroughs.
How much funding has Synthace raised?
Synthace has raised a total of $72.1M across 4 funding rounds:
Angel/Seed
$2.1M
Series A
$9.4M
Series B
$25.6M
Series C
$35M
Angel/Seed (2013): $2.1M with participation from Sofinnova Partners
Series A (2017): $9.4M led by Sofinnova Partners, SOSV, 11.2 Capital, White Cloud Capital, Bioeconomy Capital., and Amadeus Capital Partners
Series B (2018): $25.6M supported by Horizons Ventures
Series C (2021): $35M featuring Sofinnova Partners and Horizons Ventures
Key Investors in Synthace
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, with a focus on healthcare and sustainability. They are known for their hands-on approach to company building across the entire value chain of life sciences investments, from seed to later stages.
Horizons Ventures
Horizons Ventures focuses on investing in deep science and technology aimed at advancing humanity. They support innovative projects with the potential for transformative change, particularly in the science and technology sectors.
SOSV
SOSV is a multi-stage venture capital investor that provides both intellectual and financial capital to accelerate the growth of founders' ideas, with a particular interest in science and technology ventures.
What's next for Synthace?
The recent major strategic investment in Synthace signals a strong confidence in the company's trajectory and its potential to revolutionize the life sciences sector. This capital infusion is expected to fuel further development of their Antha platform, enhance their market reach, and support strategic partnerships. As Synthace continues to scale its operations and expand its technological capabilities, it is well-positioned to address critical challenges in biological research and development, driving innovation in areas such as drug discovery, synthetic biology, and personalized medicine. The company's focus on user-centric design and robust automation solutions positions it for sustained growth and impact in the rapidly evolving field of biotechnology.
See full Synthace company page
